€1.45 Billion Boost! GSK and CureVac Forge New Path in mRNA Vaccines
GSK takes lead on influenza and COVID-19 mRNA vaccines in €400M deal with CureVac.
GSK takes the lead on promising influenza and COVID-19
vaccines in a revamped collaboration with CureVac. The new licensing deal
grants GSK full control over development, manufacturing, and global sales of
these mRNA vaccine candidates.CureVac gets a financial boost with a €400
million upfront payment and potential for over €1 billion more in milestones
and royalties. This agreement allows CureVac to focus on its own pipeline while
still benefiting from the progress of the partnered vaccines.
Both companies see promise in the collaboration's potential
to deliver best-in-class vaccines. GSK will leverage its expertise to
accelerate development, while CureVac retains the rights to its broader mRNA
technology portfolio.
The legalese: The deal awaits standard regulatory approvals
before finalization.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion